-
公开(公告)号：WO2011100325A2
公开(公告)日：2011-08-18
申请号：PCT/US2011/024194
申请日：2011-02-09
Applicant: SICOR INC. , VRASPIR, Pavel , PAIOCCHI, Maurizio , JEGOROV, Alexandr , SCARPITTA, Francesca
Inventor： VRASPIR, Pavel , PAIOCCHI, Maurizio , JEGOROV, Alexandr , SCARPITTA, Francesca
IPC: C07D403/06 , A61K31/404 , A61P35/00
CPC classification number: C07D403/06
Abstract: Polymorphs of Sunitinib malate and other salts have been prepared. Compositions comprising Sunitinib base, L-malic acid and another carboxylic acid are also described. Such polymorphs and compositions are useful, for example, in preparing pharmaceutical compositions.
Abstract translation: 已经制备了苹果酸舒尼替尼和其他盐的多晶型物。 还描述了包含舒尼替尼碱，L-苹果酸和另一种羧酸的组合物。 这样的多晶型物和组合物可用于例如制备药物组合物。
-
12.发明申请POLYMORPHS OF VORINOSTAT AND VORINOSTAT POTASSIUM SALT AND PROCESS FOR PREPARATION THEREOF 审中-公开沃辛胺和沃辛酸钾的多糖及其制备方法
公开(公告)号：WO2010062333A1
公开(公告)日：2010-06-03
申请号：PCT/US2009/005837
申请日：2009-10-26
Applicant: PLUS CHEMICALS SA , TEVA PHARMACEUTICALS USA, INC. , VILLALVA-SERVIN, Nidia-Paulina , RODRIGUEZ-HERNANDEZ, Angel-Alfredo , VRASPIR, Pavel
IPC: C07C239/18
CPC classification number: C07C259/06
Abstract: Crystalline Vorinostat potassium salt form A characterized by a powder XRD pattern having peaks at about 4.9 and 7.4 ± 0.2 degrees 2-theta and any 3 peaks selected from the lis consisting of: 12.3, 19.8, 20.9, 22.1, 22.8, 28.7 and 29.5 ± 0.2 degrees 2-theta is provided. Crystalline Vorinostat potassium salt form A may be polymorphically pure. Processes for preparing crystalline Vorinostat potassium salt form A are also provided. Further provided i crystalline Vorinostat form VI characterized by a powder XRD pattern having peaks at about 14.3, 14.8, 17.6, 21.4 and 23.1 ± 0.2 degrees 2-theta as well as processes for preparing crystalline Vorinostat form VI.
Abstract translation: 结晶Vorinostat钾盐形式A，其特征在于具有在约4.9和7.4±0.2度2-θ处具有峰值的粉末XRD图案，以及选自lis的任何3个峰由12.3,19.8,20.9,22.1,22.8,28.7和29.5± 提供0.2度2-θ。 结晶伏立诺斯钾盐形式A可以是多晶型纯的。 还提供了制备结晶伏立诺他钾盐形式A的方法。 进一步提供i结晶Vorinostat形式VI，其特征在于在约14.3,14.8,17.6,21.4和23.1±0.2度2-θ处具有峰的粉末XRD图，以及制备结晶Vorinostat VI的方法。
-
公开(公告)号：WO2010039798A2
公开(公告)日：2010-04-08
申请号：PCT/US2009/058975
申请日：2009-09-30
Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , JEGOROV, Alexandr , GAVENDA, Ales , VRASPIR, Pavel , ARONHIME, Judith
Inventor： JEGOROV, Alexandr , GAVENDA, Ales , VRASPIR, Pavel , ARONHIME, Judith
IPC: A61K9/16 , A61K9/19 , A61K31/404 , A61P35/02
CPC classification number: A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/404 , C07D209/34
Abstract: Combinations of a pharmaceutically acceptable excipient selected from the group consisting of microcrystalline cellulose, polyvinylpyrrolidone, cyclodextrin, and disaccharide or derivatives thereof and acomposition of sunitinib base and L-malic acid were prepared.
Abstract translation: 制备选自微晶纤维素，聚乙烯吡咯烷酮，环糊精和二糖或其衍生物的药学上可接受的赋形剂和舒尼替尼碱和L-苹果酸的组合。
-
14.发明申请SUNITINIB HEMI-L-MALATE, POLYMORPHS AND PREPARATION THEREOF, POLYMORPHS OF RACEMIC SUNITINIB MALATE, COMPOSITINS CONTAINING SUNITINIB BASE AND MALIC ACID AND PREPARATION THEREOF 审中-公开SUNITINIB HEMI-L-MALATE，POLYMORPHS及其制备方法，季铵盐恶唑酸的多元醇，含有苯胺基和马来酸的组合物及其制备方法
公开(公告)号：WO2009067686A8
公开(公告)日：2009-07-16
申请号：PCT/US2008084386
申请日：2008-11-21
Applicant: TEVA PHARMA , TEVA PHARMA , JEGOROV ALEXANDR , GAVENDA ALES , VRASPIR PAVEL , ARONHIME JUDITH , ANGIOLETTI PAOLO , CANAVESI AUGUSTO , VILLA MARCO , SCARPITTA FRANCESCA , BIGATTI ETTORE , MACDONALD PETER LINDSAY
Inventor： JEGOROV ALEXANDR , GAVENDA ALES , VRASPIR PAVEL , ARONHIME JUDITH , ANGIOLETTI PAOLO , CANAVESI AUGUSTO , VILLA MARCO , SCARPITTA FRANCESCA , BIGATTI ETTORE , MACDONALD PETER LINDSAY
IPC: C07D403/06 , A61K31/404 , A61P35/00
CPC classification number: C07D403/06
Abstract: The invention provides Sunitinib hemi-L-malate, polymorphs thereof, polymorphs of racemic sunitinib malate, compositions containing sunitinib base and either L or racemic malic acid, processes for the preparation thereof, and pharmaceutical compositions thereof.
Abstract translation: 本发明提供舒尼替尼半苹果酸，其多晶型物，苹果酸外消旋舒尼替尼的多晶型物，含有舒尼替尼碱和L或外消旋苹果酸的组合物，其制备方法及其药物组合物。
-
15.发明申请
公开(公告)号：WO2013134534A3
公开(公告)日：2013-12-05
申请号：PCT/US2013029664
申请日：2013-03-07
Applicant: PLUS CHEMICALS S A , TEVA PHARMA , VRASPIR PAVEL , JEGOROV ALEXANDR , GABRIEL ROMAN , GAVENDA ALES
Inventor： VRASPIR PAVEL , JEGOROV ALEXANDR , GABRIEL ROMAN , GAVENDA ALES
IPC: C07D305/14 , A61K31/337 , A61P35/00
CPC classification number: C07D305/14 , C07B2200/13
Abstract: The invention relates to solid state forms of Cabazitaxel and processes for preparing the solid state forms. The invention further relates to pharmaceutical compositions and formulations comprising one or more of the solid state forms.
Abstract translation: 本发明涉及卡伐他汀的固体形式和制备固态形式的方法。 本发明还涉及包含一种或多种固态形式的药物组合物和制剂。
-
Patent Agency Ranking16.发明申请
公开(公告)号：WO2012142117A1
公开(公告)日：2012-10-18
申请号：PCT/US2012/033061
申请日：2012-04-11
Applicant: PLUS CHEMICALS SA , TEVA PHARMACEUTICALS USA, INC. , SIMO, Ondrej , VRASPIR, Pavel , HOLAS, Tomas , JEGOROV, Alexandr , GABRIEL, Roman
Inventor： SIMO, Ondrej , VRASPIR, Pavel , HOLAS, Tomas , JEGOROV, Alexandr , GABRIEL, Roman
IPC: C07D305/14 , A61K31/337 , A61P35/00
CPC classification number: C07D305/14 , C07B2200/13
Abstract: The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel. The present invention further provides pharmaceutical compositions comprising one or more of the solid state forms of Cabazitaxel, and a method of treating hormone-refractory prostate cancer.
Abstract translation: 本发明涉及卡伐他汀的固体形式，以及通过其新型合成中间体以及包含一种或多种固体形式的卡巴他赛的制剂的制备方法。 本发明进一步提供包含卡伐他汀的一种或多种固态形式的药物组合物和治疗激素难治性前列腺癌的方法。
-
17.发明申请POLYMORPHS OF BENDAMUSTINE HCL AND PROCESSES FOR PREPARATION THEREOF 审中-公开BENDAMUSTINE HCL的聚合物及其制备方法
公开(公告)号：WO2010144675A1
公开(公告)日：2010-12-16
申请号：PCT/US2010/038128
申请日：2010-06-10
Applicant: PLUS CHEMICALS SA , TEVA PHARMACEUTICALS USA, INC. , KUCHAR, Martin , KORYTAKOVA, Romana , POSPISILIK, Karel , GAVENDA, Ales , VRASPIR, Pavel , JEGOROV, Alexandr
Inventor： KUCHAR, Martin , KORYTAKOVA, Romana , POSPISILIK, Karel , GAVENDA, Ales , VRASPIR, Pavel , JEGOROV, Alexandr
IPC: A61K31/4184 , C07D235/16 , A61P35/00
CPC classification number: C07D235/16 , A61K31/4184
Abstract: Novel polymorphs of Bendamustine HC1 have been prepared and characterized. These polymorphs and pharmaceutical compositions containing them are useful, for example, in treating patients with various cancers.
Abstract translation: 已经制备和表征了苯达莫司汀HCl的新型多晶型物。 这些多晶型物和含有它们的药物组合物可用于例如治疗各种癌症的患者。
-
公开(公告)号：WO2010039798A3
公开(公告)日：2010-08-19
申请号：PCT/US2009058975
申请日：2009-09-30
Applicant: TEVA PHARMA , TEVA PHARMA , JEGOROV ALEXANDR , GAVENDA ALES , VRASPIR PAVEL , ARONHIME JUDITH
Inventor： JEGOROV ALEXANDR , GAVENDA ALES , VRASPIR PAVEL , ARONHIME JUDITH
IPC: A61K9/16 , A61K9/19 , A61K31/404 , A61P35/02
CPC classification number: A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/404 , C07D209/34
Abstract: Combinations of a pharmaceutically acceptable excipient selected from the group consisting of microcrystalline cellulose, polyvinylpyrrolidone, cyclodextrin, and disaccharide or derivatives thereof and acomposition of sunitinib base and L-malic acid were prepared.
Abstract translation: 制备选自微晶纤维素，聚乙烯吡咯烷酮，环糊精和二糖或其衍生物以及舒尼替尼碱和L-苹果酸的组合的药学上可接受的赋形剂的组合。
-
公开(公告)号：WO2009053854A3
公开(公告)日：2009-12-03
申请号：PCT/IB2008003862
申请日：2008-10-23
Applicant: TEVA PHARMA , SIMO ONDREJ , FILIPCIK JIRI , MARTAUS ALEXANDR , JEGOROV ALEXANDR , GAVENDA ALES , ARONHIME JUDITH , VRASPIR PAVEL , KOLTAI TAMAS , FAUSTMANN JIRI , GABRIEL ROMAN , TEVA PHARMA
Inventor： SIMO ONDREJ , FILIPCIK JIRI , MARTAUS ALEXANDR , JEGOROV ALEXANDR , GAVENDA ALES , ARONHIME JUDITH , VRASPIR PAVEL , KOLTAI TAMAS , FAUSTMANN JIRI , GABRIEL ROMAN
IPC: C07D417/12 , A61K31/506 , A61P35/00
CPC classification number: C07D417/12
Abstract: Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof. Formula (I).
Abstract translation: 提供达沙替尼，其溶剂合物及其结晶形式，其制备方法及其药物组合物。 式（I）。
-
20.发明申请SUNITINIB HEMI-L-MALATE, POLYMORPHS AND PREPARATION THEREOF, POLYMORPHS OF RACEMIC SUNITINIB MALATE, COMPOSITINS CONTAINING SUNITINIB BASE AND MALIC ACID AND PREPARATION THEREOF 审中-公开顺丁烯二酸-L-马来酸酯，多晶型物及其制备，狂犬病的马来酸赛尼替丁的多晶型物，含有顺丁尼特基和马来酸的复合物及其制备方法
公开(公告)号：WO2009067686A3
公开(公告)日：2009-11-12
申请号：PCT/US2008084386
申请日：2008-11-21
Applicant: TEVA PHARMA , TEVA PHARMA , JEGOROV ALEXANDR , GAVENDA ALES , VRASPIR PAVEL , ARONHIME JUDITH , ANGIOLETTI PAOLO , CANAVESI AUGUSTO , VILLA MARCO , SCARPITTA FRANCESCA , BIGATTI ETTORE , MACDONALD PETER LINDSAY
Inventor： JEGOROV ALEXANDR , GAVENDA ALES , VRASPIR PAVEL , ARONHIME JUDITH , ANGIOLETTI PAOLO , CANAVESI AUGUSTO , VILLA MARCO , SCARPITTA FRANCESCA , BIGATTI ETTORE , MACDONALD PETER LINDSAY
IPC: C07D403/06 , A61K31/404 , A61P35/00
CPC classification number: C07D403/06
Abstract: The invention provides Sunitinib hemi-L-malate, polymorphs thereof, polymorphs of racemic sunitinib malate, compositions containing sunitinib base and either L or racemic malic acid, processes for the preparation thereof, and pharmaceutical compositions thereof.
Abstract translation: 本发明提供了舒尼替尼半L-苹果酸盐，其多晶型物，外消旋苹果酸舒尼替尼的多晶型物，含有舒尼替尼碱和L或外消旋苹果酸的组合物，其制备方法及其药物组合物。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.009 seconds)
